Treatment of severe non-infectious uveitis in high-risk conditions (Part 2): systemic infections; management and safety issues

Bibliography

• Foster CS, Vitale AT, Jakobiec FA. Diagnosis and treatment of uveitis. 2nd edition. Jaypee Brothers Medical Publishers; New Delhi; London: 2013
   Google Scholar
• Nussenblatt RB, Whitcup SM. Uveitis: fundamentals and clinical practice. 4th edition. Mosby; Edinburgh: 2010
   Google Scholar
• Imrie FR, Dick AD. Nonsteroidal drugs for the treatment of noninfectious posterior and intermediate uveitis. Curr Opin Ophthalmol 2007;18(3):212-19
   PubMed Web of Science ®Google Scholar
• Bonfioli AA, Damico FM, Curi ALL, Orefice F. Intermediate uveitis. Semin Ophthalmol 2005;20(3):147-54
   PubMedGoogle Scholar
• Esterberg E, Acharya NR. Corticosteroid-sparing therapy: practice patterns among uveitis specialists. J Ophthalmic Inflamm Infect 2012;2(1):21-8
   PubMedGoogle Scholar
• Lovell DJ, Giannini EH, Reiff A, et al. Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open-label, extended-treatment trial. Arthritis Rheum 2003;48(1):218-26
   PubMed Web of Science ®Google Scholar
• Kroesen S, Widmer AF, Tyndall A, Hasler P. Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapy. Rheumatology (Oxford) 2003;42(5):617-21
   PubMed Web of Science ®Google Scholar
• Hamilton CD. Infectious complications of treatment with biologic agents. Curr Opin Rheumatol 2004;16(4):393-8
   PubMed Web of Science ®Google Scholar
• Ting PT, Koo JY. Use of etanercept in human immunodeficiency virus (HIV) and acquired immunodeficiency syndrome (AIDS) patients. Int J Dermatol 2006;45(6):689-92
   PubMed Web of Science ®Google Scholar
• World Health Organization. World Health Statistics 2014: A wealth of information on global public health. WHO Library Cataloguing-in-Publication Data; Geneva: 2014
   Google Scholar
• Vassilopoulos D, Calabrese LH. Risks of immunosuppressive therapies including biologic agents in patients with rheumatic diseases and co-existing chronic viral infections. Curr Opin Rheumatol 2007;19(6):619-25
   PubMed Web of Science ®Google Scholar
• Calabrese LH. Autoimmune manifestations of human immunodeficiency virus (HIV) infection. Clin Lab Med 1988;8(2):269-79
   PubMed Web of Science ®Google Scholar
• Calabrese LH, Kirchner E, Shrestha R. Rheumatic complications of human immunodeficiency virus infection in the era of highly active antiretroviral therapy: emergence of a new syndrome of immune reconstitution and changing patterns of disease. Semin Arthritis Rheum 2005;35(3):166-74
   PubMed Web of Science ®Google Scholar
• Mondy K, Tebas P. Emerging bone problems in patients infected with human immunodeficiency virus. Clin Infect Dis 2003;36(Suppl 2):S101-5
   Google Scholar
• Rose-Nussbaumer J, Goldstein DA, Thorne JE, et al. Uveitis in human immunodeficiency virus-infected persons with CD4+ T-lymphocyte count over 200 cells/mL. Clin Experiment Ophthalmol 2014;42(2):118-25
   PubMed Web of Science ®Google Scholar
• Calabrese LH, Albrecht M, Young J, et al. Successful cardiac transplantation in an HIV-1-infected patient with advanced disease. N Engl J Med 2003;348(23):2323-8
   PubMed Web of Science ®Google Scholar
• Roland ME, Carlson LL, Frassetto LA, Stock PG. Solid organ transplantation: referral, management, and outcomes in HIV-infected patients. AIDS Read 2006;16(12):664-8
   PubMedGoogle Scholar
• Roland ME, Stock PG. Solid organ transplantation is a reality for patients with HIV infection. Curr HIV/AIDS Rep 2006;3(3):132-8
   PubMedGoogle Scholar
• Frassetto LA, Browne M, Cheng A, et al. Immunosuppressant pharmacokinetics and dosing modifications in HIV-1 infected liver and kidney transplant recipients. Am J Transplant 2007;7(12):2816-20
   PubMed Web of Science ®Google Scholar
• Frassetto L, Floren L, Barin B, et al. Changes in clearance, volume and bioavailability of immunosuppressants when given with HAART in HIV-1 infected liver and kidney transplant recipients. Biopharm Drug Dispos 2013;34(8):442-51
   PubMed Web of Science ®Google Scholar
• Viazis N, Vlachogiannakos J, Georgiou O, et al. Course of inflammatory bowel disease in patients infected with human immunodeficiency virus. Inflamm Bowel Dis 2010;16(3):507-11
   PubMed Web of Science ®Google Scholar
• Maurer TA, Zackheim HS, Tuffanelli L, Berger TG. The use of methotrexate for treatment of psoriasis in patients with HIV infection. J Am Acad Dermatol 1994;31(2 Pt 2):372-5
   PubMed Web of Science ®Google Scholar
• Duvic M, Johnson TM, Rapini RP, et al. Acquired immunodeficiency syndrome-associated psoriasis and Reiter’s syndrome. Arch Dermatol 1987;123(12):1622-32
   PubMed Web of Science ®Google Scholar
• Winchester R, Bernstein DH, Fischer HD, et al. The co-occurrence of Reiter’s syndrome and acquired immunodeficiency. Ann Intern Med 1987;106(1):19-26
   PubMed Web of Science ®Google Scholar
• Dunn JP. Immune recovery uveitis. Hopkins HIV Rep 2001;13(6):9-10
   PubMedGoogle Scholar
• Holland GN. Immune recovery uveitis. Ocul Immunol Inflamm 1999;7(3-4):215-21
   PubMed Web of Science ®Google Scholar
• Morrison VL, Kozak I, LaBree LD, et al. Intravitreal triamcinolone acetonide for the treatment of immune recovery uveitis macular edema. Ophthalmology 2007;114(2):334-9
   PubMed Web of Science ®Google Scholar
• Pham T, Bachelez H, Berthelot J-M, et al. TNF alpha antagonist therapy and safety monitoring. Joint Bone Spine 2011;78(Suppl 1):15-185
   PubMed Web of Science ®Google Scholar
• Matsuyama T, Kobayashi N, Yamamoto N. Cytokines and HIV infection: is AIDS a tumor necrosis factor disease? AIDS 1991;5(12):1405-17
   PubMed Web of Science ®Google Scholar
• Poli G, Fauci AS. Cytokine modulation of HIV expression. Semin Immunol 1993;5(3):165-73
   PubMedGoogle Scholar
• Butera ST, Roberts BD, Folks TM. Ligand passing by the p75 tumour necrosis factor receptor enhances HIV-1 activation. Cytokine 1996;8(10):745-50
   PubMed Web of Science ®Google Scholar
• Kedzierska K, Crowe SM. Cytokines and HIV-1: interactions and clinical implications. Antivir Chem Chemother 2001;12(3):133-50
   PubMedGoogle Scholar
• Aukrust P, Liabakk NB, Müller F, et al. Serum levels of tumor necrosis factor-alpha (TNF alpha) and soluble TNF receptors in human immunodeficiency virus type 1 infection--correlations to clinical, immunologic, and virologic parameters. J Infect Dis 1994;169(2):420-4
   PubMed Web of Science ®Google Scholar
• Fine SM, Maggirwar SB, Elliott PR, et al. Proteasome blockers inhibit TNF-alpha release by lipopolysaccharide stimulated macrophages and microglia: implications for HIV-1 dementia. J Neuroimmunol 1999;95(1-2):55-64
   PubMed Web of Science ®Google Scholar
• Saha RN, Pahan K. Tumor necrosis factor-alpha at the crossroads of neuronal life and death during HIV-associated dementia. J Neurochem 2003;86(5):1057-71
   PubMed Web of Science ®Google Scholar
• Drexler AM. Tumor necrosis factor: its role in HIV/AIDS. STEP Perspect 1995;7(1):13-15
   PubMedGoogle Scholar
• Pfeffer K. Biological functions of tumor necrosis factor cytokines and their receptors. Cytokine Growth Factor Rev 2003;14(3-4):185-91
   PubMed Web of Science ®Google Scholar
• Smart T. Inhibiting TNF to preserve lean body mass. GMHC Treat Issues 1995;9(5):3
   Google Scholar
• Shannon EJ, Morales MJ, Sandoval F. Immunomodulatory assays to study structure-activity relationships of thalidomide. Immunopharmacology 1997;35(3):203-12
   PubMed Web of Science ®Google Scholar
• Grover JK, Vats V, Gopalakrishna R, Ramam M. Thalidomide: a re-look. Natl Med J India 2000;13(3):132-41
   PubMed Web of Science ®Google Scholar
• Calabrese L, Fleischer AB. Thalidomide: current and potential clinical applications. Am J Med 2000;108(6):487-95
   PubMed Web of Science ®Google Scholar
• Jacobson JM, Greenspan JS, Spritzler J, et al. Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. N Engl J Med 1997;336(21):1487-93
   PubMed Web of Science ®Google Scholar
• Cepeda EJ, Williams FM, Ishimori ML, et al. The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease. Ann Rheum Dis 2008;67(5):710-12
   PubMed Web of Science ®Google Scholar
• Ellerin T, Rubin RH, Weinblatt ME. Infections and anti-tumor necrosis factor alpha therapy. Arthritis Rheum 2003;48(11):3013-22
   PubMed Web of Science ®Google Scholar
• Wallis RS, Kyambadde P, Johnson JL, et al. A study of the safety, immunology, virology, and microbiology of adjunctive etanercept in HIV-1-associated tuberculosis. AIDS 2004;18(2):257-64
   PubMed Web of Science ®Google Scholar
• Gaylis N. Infliximab in the treatment of an HIV positive patient with Reiter’s syndrome. J Rheumatol 2003;30(2):407-11
   PubMed Web of Science ®Google Scholar
• Bartke U, Venten I, Kreuter A, et al. Human immunodeficiency virus-associated psoriasis and psoriatic arthritis treated with infliximab. Br J Dermatol 2004;150(4):784-6
   PubMed Web of Science ®Google Scholar
• Beltrán B, Nos P, Bastida G, et al. Safe and effective application of anti-TNF-alpha in a patient infected with HIV and concomitant Crohn’s disease. Gut 2006;55(11):1670-1
   PubMed Web of Science ®Google Scholar
• Alecsandru D, Padilla B, Izquierdo JAA, et al. Severe refractory hidradenitis suppurativa in an HIV-positive patient successfully treated with infliximab. Arch Dermatol 2010;146(12):1343-5
   PubMed Web of Science ®Google Scholar
• Almoallim H, Jali I, Wali G. Successful use of antitumor necrosis factor-alpha biological therapy in managing human immunodeficiency virus-associated arthritis: three case studies from Saudi Arabia. Joint Bone Spine 2013;80(4):426-8
   PubMed Web of Science ®Google Scholar
• Gaylis NB. Long-term follow-up of an HIV-infected patient with reactive arthritis treated with infliximab. J Clin Rheumatol 2012;18(3):153-4
   PubMed Web of Science ®Google Scholar
• Calabrese LH, Zein N, Vassilopoulos D. Safety of antitumour necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection. Ann Rheum Dis 2004;63(Suppl 2):ii18-24
   Google Scholar
• Frassetto L, Baluom M, Jacobsen W, et al. Cyclosporine pharmacokinetics and dosing modifications in human immunodeficiency virus-infected liver and kidney transplant recipients. Transplantation 2005;80(1):13-17
   PubMed Web of Science ®Google Scholar
• Frassetto L, Thai T, Aggarwal AM, et al. Pharmacokinetic interactions between cyclosporine and protease inhibitors in HIV+ subjects. Drug Metab Pharmacokinet 2003;18(2):114-20
   PubMedGoogle Scholar
• Vogel M, Voigt E, Michaelis H-C, et al. Management of drug-to-drug interactions between cyclosporine A and the protease-inhibitor lopinavir/ritonavir in liver-transplanted HIV-infected patients. Liver Transplant 2004;10(7):939-44
   PubMed Web of Science ®Google Scholar
• Jain AKB, Venkataramanan R, Shapiro R, et al. The interaction between antiretroviral agents and tacrolimus in liver and kidney transplant patients. Liver Transplant 2002;8(9):841-5
   PubMed Web of Science ®Google Scholar
• Guaraldi G, Cocchi S, Codeluppi M, et al. Pharmacokinetic interaction between Amprenavir/Ritonavir and FosAmprenavir on cyclosporine in two patients with human immunodeficiency virus infection undergoing orthotopic liver transplantation. Transplant Proc 2006;38(4):1138-40
   PubMed Web of Science ®Google Scholar
• Jain AB, Venkataramanan R, Eghtesad B, et al. Effect of coadministered lopinavir and ritonavir (Kaletra) on tacrolimus blood concentration in liver transplantation patients. Liver Transplant 2003;9(9):954-60
   PubMed Web of Science ®Google Scholar
• Kumar MSA, Sierka DR, Damask AM, et al. Safety and success of kidney transplantation and concomitant immunosuppression in HIV-positive patients. Kidney Int 2005;67(4):1622-9
   PubMed Web of Science ®Google Scholar
• Mazuecos A, Pascual J, Gómez E, et al. Renal transplantation in HIV-infected patients in Spain. Nefrologia 2006;26(1):113-20
   PubMed Web of Science ®Google Scholar
• World Health Organization. Prevention and control of viral hepatitis infection: framework for global action. WHO Library Cataloguing-in-Publication Data; Geneva: 2012
   Google Scholar
• World Health Organization. Global policy report on the prevention and control of viral hepatitis in WHO Member States. WHO Library Cataloguing-in-Publication Data; Geneva: 2013
   Google Scholar
• Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine 2012;30(12):2212-19
   PubMed Web of Science ®Google Scholar
• Perz JF, Armstrong GL, Farrington LA, et al. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol 2006;45(4):529-38
   PubMed Web of Science ®Google Scholar
• Chopra S. Clinical manifestations and natural history of chronic hepatitis C virus infection. UpToDate, Post TW. UpToDate, Waltham MA. Available from: http://www.uptodate.com/contents/clinical-manifestations-andnatural-history-of-chronic-hepatitis-c-virus-infection. [ Accessed on 4 February 2015 ]
   Google Scholar
• López-Serrano P, Pérez-Calle JL, Sánchez-Tembleque MD. Hepatitis B and inflammatory bowel disease: role of antiviral prophylaxis. World J Gastroenterol 2013;19(9):1342-8
   PubMed Web of Science ®Google Scholar
• Alter MJ. Epidemiology of hepatitis C virus infection. World J Gastroenterol 2007;13(17):2436-41
   PubMed Web of Science ®Google Scholar
• Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380(9859):2095-128
   PubMed Web of Science ®Google Scholar
• Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013;57(4):1333-42
   PubMed Web of Science ®Google Scholar
• Yeo W, Johnson PJ. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 2006;43(2):209-20
   PubMed Web of Science ®Google Scholar
• Calabrese LH, Zein NN, Vassilopoulos D. Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies. Ann Rheum Dis 2006;65(8):983-9
   PubMed Web of Science ®Google Scholar
• Bae JH, Sohn JH, Lee HS, et al. A fatal case of hepatitis B virus (HBV) reactivation during long-term, very-low-dose steroid treatment in an inactive HBV carrier. Clin Mol Hepatol 2012;18(2):225-8
   Google Scholar
• Chou CK, Wang LH, Lin HM, Chi CW. Glucocorticoid stimulates hepatitis B viral gene expression in cultured human hepatoma cells. Hepatology 1992;16(1):13-18
   PubMed Web of Science ®Google Scholar
• Zingarelli S, Frassi M, Bazzani C, et al. Use of tumor necrosis factor-alpha-blocking agents in hepatitis B virus-positive patients: reports of 3 cases and review of the literature. J Rheumatol 2009;36(6):1188-94
   PubMed Web of Science ®Google Scholar
• Pompili M, Biolato M, Miele L, Grieco A. Tumor necrosis factor-α inhibitors and chronic hepatitis C: a comprehensive literature review. World J Gastroenterol 2013;19(44):7867-73
   PubMed Web of Science ®Google Scholar
• Dai M-S, Chao T-Y, Kao W-Y, et al. Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP. Ann Hematol 2004;83(12):769-74
   PubMed Web of Science ®Google Scholar
• Perceau G, Diris N, Estines O, et al. Late lethal hepatitis B virus reactivation after rituximab treatment of low-grade cutaneous B-cell lymphoma. Br J Dermatol 2006;155(5):1053-6
   PubMed Web of Science ®Google Scholar
• Furst DE, Keystone EC, So AK, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012. Ann Rheum Dis 2013;72 Suppl 2:ii2-34.
   Google Scholar
• Mitroulis I, Hatzara C, Kandili A, et al. Long-term safety of rituximab in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection. Ann Rheum Dis 2013;72:308-10
   PubMed Web of Science ®Google Scholar
• Pei SN, Ma MC, Wang MC, et al. Analysis of hepatitis B surface antibody titers in B cell lymphoma patients after rituximab therapy. Ann Hematol 2012;91:1007-12
   PubMed Web of Science ®Google Scholar
• Furst DE, Breedveld FC, Kalden JR, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007. Ann Rheum Dis 2007;66(Suppl 3):iii2-22
   PubMed Web of Science ®Google Scholar
• Domm S, Cinatl J, Mrowietz U. The impact of treatment with tumour necrosis factor-alpha antagonists on the course of chronic viral infections: a review of the literature. Br J Dermatol 2008;159(6):1217-28
   PubMed Web of Science ®Google Scholar
• Guidotti LG, Chisari FV. Noncytolytic control of viral infections by the innate and adaptive immune response. Annu Rev Immunol 2001;19:65-91
   PubMed Web of Science ®Google Scholar
• Kasahara S, Ando K, Saito K, et al. Lack of tumor necrosis factor alpha induces impaired proliferation of hepatitis B virus-specific cytotoxic T lymphocytes. J Virol 2003;77(4):2469-76
   PubMed Web of Science ®Google Scholar
• Schlaak JF, Tully G, Löhr HF, et al. HBV-specific immune defect in chronic hepatitis B (CHB) is correlated with a dysregulation of pro- and anti-inflammatory cytokines. Clin Exp Immunol 1999;115(3):508-14
   PubMed Web of Science ®Google Scholar
• Herbein G, O’Brien WA. Tumor necrosis factor (TNF)-alpha and TNF receptors in viral pathogenesis. Proc Soc Exp Biol Med 2000;223(3):241-57
   PubMed Web of Science ®Google Scholar
• Tanaka E, Urata Y. Risk of hepatitis B reactivation in patients treated with tumor necrosis factor-α inhibitors. Hepatol Res 2012;42(4):333-9
   PubMed Web of Science ®Google Scholar
• Loras C, Gisbert JP, Mínguez M, et al. Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immunosuppressive therapy. Gut 2010;59(10):1340-6
   PubMed Web of Science ®Google Scholar
• Shale MJ, Seow CH, Coffin CS, et al. Review article: chronic viral infection in the anti-tumour necrosis factor therapy era in inflammatory bowel disease. Aliment Pharmacol Ther 2010;31(1):20-34
   PubMed Web of Science ®Google Scholar
• Toruner M, Loftus EV, Harmsen WS, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology 2008;134(4):929-36
   PubMed Web of Science ®Google Scholar
• Garcia-Vidal C, Rodríguez-Fernández S, Teijón S, et al. Risk factors for opportunistic infections in infliximab-treated patients: the importance of screening in prevention. Eur J Clin Microbiol Infect Dis 2009;28(4):331-7
   PubMed Web of Science ®Google Scholar
• Vassilopoulos D, Calabrese LH. Hepatitis C virus infection and vasculitis: implications of antiviral and immunosuppressive therapies. Arthritis Rheum 2002;46(3):585-97
   PubMed Web of Science ®Google Scholar
• Lake-Bakaar G, Dustin L, McKeating J, et al. Hepatitis C virus and alanine aminotransferase kinetics following B-lymphocyte depletion with rituximab: evidence for a significant role of humoral immunity in the control of viremia in chronic HCV liver disease. Blood 2007;109(2):845-6
   PubMed Web of Science ®Google Scholar
• Sansonno D, De Re V, Lauletta G, et al. Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20. Blood 2003;101(10):3818-26
   PubMed Web of Science ®Google Scholar
• Zaja F, De Vita S, Mazzaro C, et al. Efficacy and safety of rituximab in type II mixed cryoglobulinemia. Blood 2003;101(10):3827-34
   PubMed Web of Science ®Google Scholar
• Geri G, Terrier B, Imbert-Bismut F, et al. Evolution of biomarkers of liver fibrosis and liver insufficiency in hepatitis C virus-infected patients treated with pegylated interferon plus ribavirin and rituximab. J Viral Hepat 2012;19(7):497-500
   PubMed Web of Science ®Google Scholar
• Roux CH, Brocq O, Breuil V, et al. Safety of anti-TNF-alpha therapy in rheumatoid arthritis and spondylarthropathies with concurrent B or C chronic hepatitis. Rheumatology (Oxford) 2006;45(10):1294-7
   PubMed Web of Science ®Google Scholar
• Peterson JR, Hsu FC, Simkin PA, Wener MH. Effect of tumour necrosis factor alpha antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection. Ann Rheum Dis 2003;62(11):1078-82
   PubMed Web of Science ®Google Scholar
• Parke FA, Reveille JD. Anti-tumor necrosis factor agents for rheumatoid arthritis in the setting of chronic hepatitis C infection. Arthritis Rheum 2004;51(5):800-4
   PubMed Web of Science ®Google Scholar
• Vauloup C, Krzysiek R, Greangeot-Keros L, et al. Effects of tumor necrosis factor antagonist treatment on hepatitis C-related immunological abnormalities. Eur Cytokine Netw 2006;17(4):290-3
   PubMed Web of Science ®Google Scholar
• Aslanidis S, Vassiliadis T, Pyrpasopoulou A, et al. Inhibition of TNFalpha does not induce viral reactivation in patients with chronic hepatitis C infection: two cases. Clin Rheumatol 2007;26(2):261-4
   PubMed Web of Science ®Google Scholar
• Marotte H, Fontanges E, Bailly F, et al. Etanercept treatment for three months is safe in patients with rheumatological manifestations associated with hepatitis C virus. Rheumatology (Oxford) 2007;46(1):97-9
   PubMed Web of Science ®Google Scholar
• Tilg H, Wilmer A, Vogel W, et al. Serum levels of cytokines in chronic liver diseases. Gastroenterology 1992;103(1):264-74
   PubMed Web of Science ®Google Scholar
• Nelson DR, Lim HL, Marousis CG, et al. Activation of tumor necrosis factor-alpha system in chronic hepatitis C virus infection. Dig Dis Sci 1997;42(12):2487-94
   PubMed Web of Science ®Google Scholar
• Zylberberg H, Rimaniol AC, Pol S, et al. Soluble tumor necrosis factor receptors in chronic hepatitis C: a correlation with histological fibrosis and activity. J Hepatol 1999;30(2):185-91
   PubMed Web of Science ®Google Scholar
• Ray RB, Meyer K, Steele R, et al. Inhibition of tumor necrosis factor (TNF-alpha)-mediated apoptosis by hepatitis C virus core protein. J Biol Chem 1998;273(4):2256-9
   PubMed Web of Science ®Google Scholar
• Larrea E, Garcia N, Qian C, et al. Tumor necrosis factor alpha gene expression and the response to interferon in chronic hepatitis C. Hepatology 1996;23(2):210-17
   PubMed Web of Science ®Google Scholar
• Arase Y, Ikeda K, Chayama K, et al. Fluctuation patterns of HCV-RNA serum level in patients with chronic hepatitis. C. J, Gastroenterol 2000;35(3):221-5
   Web of Science ®Google Scholar
• Lok A. Diagnosis of hepatitis B virus infection. In: UpToDate, Post TW (Ed), UpToDate, Waltham MA. Available from: http://www.uptodate.com/contents/diagnosis-of-hepatitis-b-virus-infection. [ Accessed on 5 February 2015]
   Google Scholar
• Lorenz R, Endres S. Clinical manifestations, diagnosis, and treatment of acute hepatitis C in adults. In: UpToDate, Post TW (Ed), UpToDate, Waltham MA. Available from: http://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-treatment-of-acute-hepatitis-c-in-adults. [ Accessed on 5 February 2015
   Google Scholar
• Sharma SK, Saini N, Chwla Y. Hepatitis B virus: inactive carriers. Virol J 2005;2:82
   PubMed Web of Science ®Google Scholar
• Hui C-K, Bowden S, Jackson K, et al. Clinical significance of intrahepatic hepatitis B virus covalently closed circular DNA in chronic hepatitis B patients who received cytotoxic chemotherapy. Blood 2005;105(6):2616-17
   PubMed Web of Science ®Google Scholar
• Harigai M, Mochida S, Mimura T, et al. A proposal for management of rheumatic disease patients with hepatitis B virus infection receiving immunosuppressive therapy. Mod Rheumatol 2014;24(1):1-7
   PubMed Web of Science ®Google Scholar
• Umemura T, Kiyosawa K. Fatal HBV reactivation in a subject with anti-HBs and anti-HBc. Intern Med 2006;45(12):747-8
   PubMed Web of Science ®Google Scholar
• Umemura T, Tanaka E, Kiyosawa K, et al. Mortality secondary to fulminant hepatic failure in patients with prior resolution of hepatitis B virus infection in Japan. Clin Infect 2008;47(5):e52-6
   PubMed Web of Science ®Google Scholar
• Lok ASF, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009;50(3):661-2
   PubMed Web of Science ®Google Scholar
• Croagh CMN, Desmond PV, Bell SJ. Genotypes and viral variants in chronic hepatitis B: A review of epidemiology and clinical relevance. World J Hepatol 2015;7(3):289-303
   PubMedGoogle Scholar
• Lazarevic I. Clinical implications of hepatitis B virus mutations: Recent advances. World J Gastroenterol 2014;20(24):7653-64
   PubMed Web of Science ®Google Scholar
• Lau GK, Yiu HH, Fong DY, et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology 2003;125(6):1742-9
   PubMed Web of Science ®Google Scholar
• Hou JK, Velayos F, Terrault N, Mahadevan U. Viral hepatitis and inflammatory bowel disease. Inflamm Bowel Dis 2010;16(6):925-32
   PubMed Web of Science ®Google Scholar
• Hatzakis A, Wait S, Bruix J, et al. The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference*. J Viral Hepat 2011;18(Suppl 1):1-16
   PubMed Web of Science ®Google Scholar
• Ayoub WS, Keeffe EB. Review article: current antiviral therapy of chronic hepatitis B. Aliment Pharmacol Ther 2011;34(10):1145-58
   PubMed Web of Science ®Google Scholar
• European Association For The Study Of The Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009;50(2):227-42
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Chaparro M, Esteve M. Review article: prevention and management of hepatitis B and C infection in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2011;33(6):619-33
   PubMed Web of Science ®Google Scholar
• Rahier JF, Ben-Horin S, Chowers Y, et al. European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis 2009;3(2):47-91
   PubMed Web of Science ®Google Scholar
• Reid CT, De Gascun C, Hall W, et al. Is universal screening for hepatitis C infection prior to commencing antitumour necrosis factor-α therapy necessary? Br J Dermatol 2013;169(6):1319-21
   PubMed Web of Science ®Google Scholar
• World Health Organization. Global Tuberculosis Report 2014. WHO Library Cataloguing-in-Publication Data; Geneva: 2014
   Google Scholar
• Askling J, Fored CM, Brandt L, et al. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum 2005;52(7):1986-92
   PubMed Web of Science ®Google Scholar
• Wallis RS. Mathematical modeling of the cause of tuberculosis during tumor necrosis factor blockade. Arthritis Rheum 2008;58(4):947-52
   PubMed Web of Science ®Google Scholar
• Gómez-Reino JJ, Carmona L, Valverde VR, et al. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 2003;48(8):2122-7
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Latent tuberculosis infection: a guide for primary health care providers. Atlanta, Georgia: U.S. Department of Health and Human Services Centers for Disease Control and Prevention National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention Division of Tuberculosis Elimination; 2013
   Google Scholar
• McKinney JD, Höner zu Bentrup K, Muñoz-Elías EJ, et al. Persistence of Mycobacterium tuberculosis in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase. Nature 2000;406(6797):735-8
   PubMed Web of Science ®Google Scholar
• Fauci A, Braunwald E, Eugene AS, et al. Harrison’s Principles of Internal Medicine. 17 edition. McGraw-Hill; New York: 2008
   Google Scholar
• Gupta V, Gupta A, Rao NA. Intraocular tuberculosis - an update. Surv Ophthalmol 2007;52(6):561-87
   PubMed Web of Science ®Google Scholar
• Vasconcelos-Santos DV, Zierhut M, Rao NA. Strengths and weaknesses of diagnostic tools for tuberculous uveitis. Ocul Immunol Inflamm 2009;17(5):351-5
   PubMed Web of Science ®Google Scholar
• Abu El-Asrar AM, Abouammoh M, Al-Mezaine HS. Tuberculous uveitis. Int Ophthalmol Clin 2010;50(2):19-39
   PubMedGoogle Scholar
• Gupta A, Gupta V. Tubercular posterior uveitis. Int Ophthalmol Clin 2005;45(2):71-88
   PubMedGoogle Scholar
• Tabbara KF. Tuberculosis. Curr Opin Ophthalmol 2007;18(6):493-501
   PubMed Web of Science ®Google Scholar
• Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society. MMWR Recomm Rep 2000;49(RR-6):1-51
   Google Scholar
• Mazurek GH, Jereb J, Vernon A, et al. Updated guidelines for using interferon gamma release assays to detect mycobacterium tuberculosis infection - United States, 2010. MMWR Recomm Rep 2010;59(RR-5):1-25
   PubMedGoogle Scholar
• Albini TA, Karakousis PC, Rao NA. Interferon-gamma release assays in the diagnosis of tuberculous uveitis. Am J Ophthalmol 2008;146(4):486-8
   PubMed Web of Science ®Google Scholar
• Lalvani A. Diagnosing tuberculosis infection in the 21st century: new tools to tackle an old enemy. Chest 2007;131(6):1898-906
   PubMed Web of Science ®Google Scholar
• González-Martín J, García-García JM, Anibarro L, et al. Consensus document on the diagnosis, treatment and prevention of tuberculosis. Arch Bronconeumol 2010;46(5):255-74
   PubMed Web of Science ®Google Scholar
• Tuberculosis Clinical diagnosis and management of tuberculosis, and measures for its prevention and control. National Institute for Health and Care Excellence (NICE) Clinical Guideline 117. London. 2011. Available from: http://www.nice.org.uk/guidance/cg117/resources/guidance-tuberculosis-pdf [Last accessed 24 February 2015]
   Google Scholar
• Zorlu M, Kiskac M, Karatoprak C, et al. Pott’s disease and hypercalcemia in a patient with rheumatoid arthritis receiving methotrexate monotherapy. Indian J Pharmacol 2013;45(6):631-3
   PubMed Web of Science ®Google Scholar
• Binymin K, Cooper RG. Late reactivation of spinal tuberculosis by low-dose methotrexate therapy in a patient with rheumatoid arthritis. Rheumatology (Oxford) 2001;40(3):341-2
   PubMed Web of Science ®Google Scholar
• Chen Y-J, Wu C-Y, Shen J-L, et al. Association between traditional systemic antipsoriatic drugs and tuberculosis risk in patients with psoriasis with or without psoriatic arthritis: results of a nationwide cohort study from Taiwan. J Am Acad Dermatol 2013;69(1):25-33
   PubMed Web of Science ®Google Scholar
• Dixon WG, Hyrich KL, Watson KD, et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). Ann Rheum Dis 2010;69(3):522-8
   PubMed Web of Science ®Google Scholar
• Bogas M, Machado P, Mourão AF, et al. Methotrexate treatment in rheumatoid arthritis: management in clinical remission, common infection and tuberculosis. Results from a systematic literature review. Clin Rheumatol 2010;29(6):629-35
   PubMed Web of Science ®Google Scholar
• Vadillo Font C, Hernández-García C, Pato E, et al. Incidence and characteristics of tuberculosis in patients with autoimmune rheumatic diseases. Rev Clínica Esp 2003;203(4):178-82
   PubMed Web of Science ®Google Scholar
• Smolen JS, Keystone EC, Emery P, et al. Consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 2007;66(2):143-50
   PubMed Web of Science ®Google Scholar
• Buch MH, Smolen JS, Betteridge N, et al. Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 2011;70(6):909-20
   PubMed Web of Science ®Google Scholar
• Mohrbacher A. B cell non-Hodgkin’s lymphoma: rituximab safety experience. Arthritis Res Ther 2005;7(Suppl 3):S19-25
   Google Scholar
• Emery P, Fleischmann R, Filipowicz-Sosnowska A, et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006;54(5):1390-400
   PubMed Web of Science ®Google Scholar
• Edwards JCW, Szczepanski L, Szechinski J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004;350(25):2572-81
   PubMed Web of Science ®Google Scholar
• Ottaviani S, Tiendrebeogo J, Choudat L, et al. Knee tuberculosis under rituximab therapy for rheumatoid arthritis. Joint Bone Spine 2013;80(4):435-6
   PubMed Web of Science ®Google Scholar
• Jick SS, Lieberman ES, Rahman MU, Choi HK. Glucocorticoid use, other associated factors, and the risk of tuberculosis. Arthritis Rheum 2006;55(1):19-26
   PubMed Web of Science ®Google Scholar
• Cantini F, Niccoli L, Goletti D. Tuberculosis risk in patients treated with non-anti-tumor necrosis factor-α (TNF-α) targeted biologics and recently licensed TNF-α inhibitors: data from clinical trials and national registries. J Rheumatol Suppl 2014;91:56-64
   PubMedGoogle Scholar
• Ulrichs T, Kosmiadi GA, Trusov V, et al. Human tuberculous granulomas induce peripheral lymphoid follicle-like structures to orchestrate local host defence in the lung. J Pathol 2004;204(2):217-28
   PubMed Web of Science ®Google Scholar
• Maglione PJ, Xu J, Chan J. B cells moderate inflammatory progression and enhance bacterial containment upon pulmonary challenge with Mycobacterium tuberculosis. J Immunol 2007;178(11):7222-34
   PubMed Web of Science ®Google Scholar
• Chen Y-M, Chen H-H, Lai K-L, et al. The effects of rituximab therapy on released interferon-γ levels in the QuantiFERON assay among RA patients with different status of Mycobacterium tuberculosis infection. Rheumatology (Oxford) 2013;52(4):697-704
   PubMed Web of Science ®Google Scholar
• Goldbach-Mansky R, Kastner DL. Autoinflammation: the prominent role of IL-1 in monogenic autoinflammatory diseases and implications for common illnesses. J Allergy Clin Immunol 2009;124(6):1141-9
   PubMed Web of Science ®Google Scholar
• Nam JL, Winthrop KL, van Vollenhoven RF, et al. Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. Ann Rheum Dis 2010;69(6):976-86
   PubMed Web of Science ®Google Scholar
• Schiff MH, Kremer JM, Jahreis A, et al. Integrated safety in tocilizumab clinical trials. Arthritis Res Ther 2011;13(5):R141
   PubMed Web of Science ®Google Scholar
• Koike T, Harigai M, Inokuma S, et al. Postmarketing surveillance of tocilizumab for rheumatoid arthritis in Japan: interim analysis of 3881 patients. Ann Rheum Dis 2011;70(12):2148-51
   PubMed Web of Science ®Google Scholar
• Carmona L, Gómez-Reino JJ, Rodríguez-Valverde V, et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 2005;52(6):1766-72
   PubMed Web of Science ®Google Scholar
• Gómez-Reino JJ, Carmona L, Angel Descalzo M; Biobadaser Group. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum 2007;57(5):756-61
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention (CDC). Tuberculosis associated with blocking agents against tumor necrosis factor-alpha--California, 2002-2003. MMWR Morb Mortal Wkly Rep 2004;53(30):683-6
   PubMedGoogle Scholar
• Tubach F, Salmon D, Ravaud P, et al. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum 2009;60(7):1884-94
   PubMed Web of Science ®Google Scholar
• Furst DE, Wallis R, Broder M, Beenhouwer DO. Tumor necrosis factor antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infection. Semin Arthritis Rheum 2006;36(3):159-67
   PubMed Web of Science ®Google Scholar
• Gan J, Manadan AM, Sequiera W, Block JA. Tuberculosis infections and tumor necrosis factor alpha antagonists. Am J Ther 2013;20(1):73-8
   PubMed Web of Science ®Google Scholar
• Flynn JL, Goldstein MM, Chan J, et al. Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity 1995;2(6):561-72
   PubMed Web of Science ®Google Scholar
• Ehlers S, Benini J, Kutsch S, et al. Fatal granuloma necrosis without exacerbated mycobacterial growth in tumor necrosis factor receptor p55 gene-deficient mice intravenously infected with Mycobacterium avium. Infect Immun 1999;67(7):3571-9
   PubMed Web of Science ®Google Scholar
• Lin PL, Myers A, Smith L, et al. Tumor necrosis factor neutralization results in disseminated disease in acute and latent Mycobacterium tuberculosis infection with normal granuloma structure in a cynomolgus macaque model. Arthritis Rheum 2010;62(2):340-50
   PubMed Web of Science ®Google Scholar
• Recommandations nationales: Prévention et prise en charge des tuberculoses survenant sous anti-TNFα] Agence française de sécurité sanitaire des produits de santé (AFSSAPS). Saint-Denis. 2005. Available from: http://ansm.sante.fr/var/ansm_site/storage/original/application/0d7318ac8b672f9dbac0a7690a213eac.pdf [Last accessed 24 February 2015]
   Google Scholar
• Kwakernaak AJ, Houtman PM, Weel JFL, et al. A comparison of an interferon-gamma release assay and tuberculin skin test in refractory inflammatory disease patients screened for latent tuberculosis prior to the initiation of a first tumor necrosis factor α inhibitor. Clin Rheumatol 2011;30(4):505-10
   PubMed Web of Science ®Google Scholar
• Winthrop KL, Weinblatt ME, Daley CL. You can’t always get what you want, but if you try sometimes (with two tests-TST and IGRA- for tuberculosis) you get what you need. Ann Rheum Dis 2012;71(11):1757-60
   PubMed Web of Science ®Google Scholar
• Sichletidis L, Settas L, Spyratos D, et al. Tuberculosis in patients receiving anti-TNF agents despite chemoprophylaxis. Int J Tuberc Lung Dis 2006;10(10):1127-32
   PubMed Web of Science ®Google Scholar
• Elbek O, Uyar M, Aydin N, et al. Increased risk of tuberculosis in patients treated with antitumor necrosis factor alpha. Clin Rheumatol 2009;28(4):421-6
   PubMed Web of Science ®Google Scholar
• Suh YS, Kwok S-K, Ju JH, et al. Safe re-administration of tumor necrosis factor-alpha (TNFα) inhibitors in patients with rheumatoid arthritis or ankylosing spondylitis who developed active tuberculosis on previous anti-TNFα therapy. J Korean Med Sci 2014;29(1):38-42
   PubMed Web of Science ®Google Scholar
• Angelucci E, Cesarini M, Vernia P. Successful resolution of pneumonia developed in a patient affected by Crohn’s disease, rheumatoid arthritis, myasthenia gravis and recurrent uveitis during concomitant treatment with tumour necrosis factor alpha inhibitors and conventional immunosuppressive drugs. Rheumatol Int 2010;30(7):977-8
   PubMed Web of Science ®Google Scholar
• Pamuk GE, Pamuk ON, Tabak F, et al. Systemic Nocardia infection in a patient with Behçet’s disease. Rheumatology (Oxford) 2001;40(5):597-9
   PubMed Web of Science ®Google Scholar
• Malkin J, Shrimpton A, Wiselka M, et al. Olecranon bursitis secondary to Mycobacterium kansasii infection in a patient receiving infliximab for Behcet’s disease. J Med Microbiol 2009;58(Pt 3):371-3
   PubMed Web of Science ®Google Scholar
• Klaeger AJ, Herbort CP. Acute acquired toxoplasmic retinochoroiditis in a patient with anterior uveitis, amplified by immunosuppressive therapy. Int Ophthalmol 2009;29(3):191-3
   PubMedGoogle Scholar
• Zaborowski AG. Cytomegalovirus retinitis following intravitreal triamcinolone acetonide in a patient with chronic uveitis on systemic immunosuppression. Ocul Immunol Inflamm 2013;21(2):148-9
   PubMed Web of Science ®Google Scholar
• Jones NP, Pickford M. Nurse-led formal health review for immunosuppressed patients with uveitis. Eye (Lond) 2009;23(6):1400-3
   PubMed Web of Science ®Google Scholar
• Walker RE, Spooner KM, Kelly G, et al. Inhibition of immunoreactive tumor necrosis factor-alpha by a chimeric antibody in patients infected with human immunodeficiency virus type 1. J Infect Dis 1996;174(1):63-8
   PubMed Web of Science ®Google Scholar
• Sha BE, Valdez H, Gelman RS, et al. Effect of etanercept (Enbrel) on interleukin 6, tumor necrosis factor alpha, and markers of immune activation in HIV-infected subjects receiving interleukin 2. AIDS Res Hum Retroviruses 2002;18(9):661-5
   PubMed Web of Science ®Google Scholar
• Marzano A, Angelucci E, Andreone P, et al. Prophylaxis and treatment of hepatitis B in immunocompromised patients. Dig Liver 2007;39(5):397-408
   PubMedGoogle Scholar
• Weinbaum CM, Williams I, Mast EE, et al. Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm Rep 2008;57(RR-8):1-20
   PubMedGoogle Scholar
• Zingarelli S, Airò P, Frassi M, et al. Prophylaxis and therapy of HBV infection in 20 patients treated with disease modifying antirheumatic drugs or with biological agents for rheumatic diseases. Reumatismo 2008;60(1):22-7
   PubMedGoogle Scholar